


Algoritmo de tratamiento hipolipemiantre en prevención CV

(diciembre, 2015)



CV: cardiovascular; SCA: síndrome coronario agudo; DM: diabetes mellitus; SCORE: Systemic Coronary Risk Evaluation (Recomendado en Andalucía). (*) Estatinas con relación coste-efectividad más favorable en nuestro medio. Simvastatina: dosis en función de riesgo CV, edad, tolerabilidad, preferencias del paciente y/o tratamientos concomitantes. SCA: si no se tolera atorvastatina 80 mg/d ↓ dosis a 40 mg/d. (#) Antecedentes enfermedad CV, obesidad, sedentarismo.

Bibliografía:

- Perk J et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J.* 2012; 33(13):1635-701.
- Deanfield J et al. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). *Heart.* 2014; 100(Suppl 2):ii1-ii67.
- NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. GC181. 2014.
- Navarro Moya FJ et al. Riesgo Vascular. *PAI.* 2010.
- Stone NJ et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;63(25 Pt B):2889-934.
- VA/DoD. Clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2014.
- Los lípidos como factor de riesgo cardiovascular: tratamiento farmacológico. *INFAC.* 2014; 22(7): 37-43.
- Reiner Z et al. ESC/EAS Guidelines for the management of dyslipidemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J.* 2011; 32(14):1769-818.